1989
A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis
Search citation statements
Paper Sections
Select...
12
5
1
1
Citation Types
0
18
0
0
Year Published
1992
2022
Publication Types
Select...
19
Relationship
0
19
Authors
Journals
Cited by 19 publications
(18 citation statements)
References 0 publications
0
18
0
0
“…The mycological cure rate was 87.1% in the terbinafine group ( n = 32), 54.8% in the griseofulvin group ( n = 32) ( P < 0.05), and the complete cure rates were 83.9% versus 41.9%, respectively, indicating the usefulness of terbinafine. The other two RCT 125,126 showed no significant difference between the two drugs, but both drugs were observed to be useful for the disease. The main side‐effects were headache, gastrointestinal symptoms and hepatic dysfunction in all RCT.…”
Section: Cq9: Is An Oral Antifungal Agent Recommended For Tinea Corporis/cruris Treatment?mentioning
confidence: 86%
“…The mycological cure rate was 87.1% in the terbinafine group ( n = 32), 54.8% in the griseofulvin group ( n = 32) ( P < 0.05), and the complete cure rates were 83.9% versus 41.9%, respectively, indicating the usefulness of terbinafine. The other two RCT 125,126 showed no significant difference between the two drugs, but both drugs were observed to be useful for the disease. The main side‐effects were headache, gastrointestinal symptoms and hepatic dysfunction in all RCT.…”
Section: Cq9: Is An Oral Antifungal Agent Recommended For Tinea Corporis/cruris Treatment?mentioning
confidence: 86%
“…in their study reported 87% clinical cure rate in patients with tinea corporis treated with terbinafine 500 mg/day. [17] Similarly, Hay et al . reported 100% cure rates in patients with tinea pedis treated with terbinafine 250 mg twice daily.…”
Section: Discussionmentioning
confidence: 98%
“…Extensive superficial lesions or lesions with papules and pustules require oral therapy [ 2 , 35 – 37 ]. As discussed earlier, experts favoured the use of combination therapy in such patients and patients with recalcitrant infection.…”
Section: Discussionmentioning
confidence: 99%
